....Most biotechs in clinical trials trade around the $1-$2 level. The insulin market is a $39 billion dollar a year industry. As news starts to spread about AAGP and the company that owns it we will see a rush to own the stock as people will start to realize that the AAGP molecule won't be unknown for long. If the company was trying to get the molecule into trials by itself it would take years. Having the Edmonton Protocol and Dr Shapiros team and the Univ of Alberta as sponsors makes this application an incredible feat. The possibilities are endless.